Analysts Set LifeMD, Inc. (NASDAQ:LFMD) Price Target at $11.43

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have been given an average rating of "Buy" by the seven analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $11.43.

Several equities research analysts have recently weighed in on the company. HC Wainwright raised their price objective on LifeMD from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $15.00 price target on shares of LifeMD in a research report on Tuesday, March 11th. KeyCorp cut their price objective on LifeMD from $10.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Lake Street Capital started coverage on shares of LifeMD in a research report on Tuesday, December 10th. They issued a "buy" rating and a $12.00 target price on the stock. Finally, B. Riley upgraded shares of LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th.

LifeMD Price Performance

Shares of NASDAQ LFMD traded down $0.16 during mid-day trading on Tuesday, reaching $5.16. 1,320,460 shares of the company traded hands, compared to its average volume of 809,459. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The firm has a market cap of $230.05 million, a PE ratio of -8.06 and a beta of 2.22. The stock has a fifty day simple moving average of $5.86 and a 200-day simple moving average of $5.44.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The firm had revenue of $64.26 million for the quarter, compared to analyst estimates of $57.43 million. As a group, analysts predict that LifeMD will post -0.56 EPS for the current fiscal year.

Insider Activity at LifeMD

In related news, CMO Jessica Friedeman sold 30,000 shares of LifeMD stock in a transaction on Friday, March 14th. The stock was sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the sale, the chief marketing officer now owns 170,000 shares of the company's stock, valued at approximately $962,200. This trade represents a 15.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $7.55, for a total value of $377,500.00. Following the completion of the transaction, the chief executive officer now owns 2,653,715 shares in the company, valued at $20,035,548.25. This trade represents a 1.85 % decrease in their position. The disclosure for this sale can be found here. 15.97% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LifeMD

Several institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC bought a new position in LifeMD during the fourth quarter valued at approximately $51,000. Oxford Asset Management LLP bought a new position in shares of LifeMD during the 4th quarter valued at $52,000. Balyasny Asset Management L.P. acquired a new stake in shares of LifeMD in the 4th quarter valued at $52,000. Intech Investment Management LLC acquired a new stake in shares of LifeMD in the 3rd quarter valued at $54,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in LifeMD in the fourth quarter worth $56,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.